AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Potassium channel subfamily T member 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6UVM3

UPID:

KCNT2_HUMAN

Alternative names:

Sequence like an intermediate conductance potassium channel subunit; Sodium and chloride-activated ATP-sensitive potassium channel Slo2.1

Alternative UPACC:

Q6UVM3; Q3SY59; Q5VTN1; Q6ZMT3

Background:

Potassium channel subfamily T member 2, also known as Slo2.1, is an outward rectifying potassium channel. It is activated by high intracellular sodium and chloride levels and plays a crucial role in maintaining the cell's electrical stability. Slo2.1 is inhibited by ATP and certain inhalation anesthetics like isoflurane, and its activity decreases upon stimulation of G-protein coupled receptors such as CHRM1 and GRM1.

Therapeutic significance:

Slo2.1 is implicated in Developmental and Epileptic Encephalopathy 57 (DEE57), a severe early-onset epilepsy with neurodevelopmental impairment. Given its role in this condition, targeting Slo2.1 could offer new avenues for therapeutic intervention in DEE57 and potentially other related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.